{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.3","upperLimit":"98.4","value":"88.9"},{"groupId":"OG001","lowerLimit":"78.0","upperLimit":"96.6","value":"91.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Overall survival by disease risk stratification after CVDD. OS: time from initiation of therapy until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants eligible for risk stratification with High-Risk Myeloma.\n\nArm A:\n\n* Level 1: Cyclophosphamide 250 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Level 2: Cyclophosphamide 500 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Level 3: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Level 4: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.3 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n\nArm B:\n\nCyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as Arm A.","id":"OG000","title":"High-Risk Myeloma"},{"description":"Participants eligible for risk stratification with Standard-Risk Myeloma.\n\nArm A:\n\n* Level 1: Cyclophosphamide 250 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Level 2: Cyclophosphamide 500 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Level 3: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Level 4: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.3 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n\nArm B:\n\nCyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule Arm A.","id":"OG001","title":"Standard-Risk Myeloma"}],"paramType":"NUMBER","populationDescription":"Participants with cytogenetics and fluorescence in situ hybridisation (FISH) results available for risk stratification.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Phase II: Two Year Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}